Full Text Journal Articles by
Author Marc S Sabatine

Advertisement

Find full text journal articles






EMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction.

Vanita R Aroda, Marc S Sabatine,

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(12):932-933]

Cited: 0 times

View full text PDF listing >>



Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients with Cardiometabolic Disease.

Nicholas A Marston, Parth N Patel, Frederick K Kamanu, Francesco Nordio, Giorgio M Melloni, Carolina Roselli, Yared Gurmu, Lu-Chen Weng, Marc P Bonaca, Robert P Giugliano, Benjamin M Scirica, Michelle L O'Donoghue, Christopher P Cannon, Christopher D Anderson, Deepak L Bhatt, Philippe Gabriel Steg, Marc Cohen, Robert F Storey, Peter Sever, Anthony C Keech, Itamar Raz, Ofri Mosenzon, Elliott M Antman, Eugene Braunwald, Patrick T Ellinor, Steven A Lubitz, Marc S Sabatine, Christian T Ruff,

Background: Genome-wide association studies have identified single nucleotide polymorphisms (SNPs) that are associated with an increased risk of stroke. We sought to determine whether a genetic risk score (GRS) could identify subjects at higher risk for ischemic stroke after accounting for traditional clinical risk factors in five trials across the ... Read more >>

Circulation (Circulation)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization.

Kazuma Oyama, Remo H M Furtado, Antonio Fagundes, Thomas A Zelniker, Minao Tang, Julia Kuder, Sabina A Murphy, Andrew Hamer, Huei Wang, Anthony C Keech, Robert P Giugliano, Marc S Sabatine, Brian A Bergmark,

BACKGROUND:Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors induce plaque regression and reduce the risk of coronary revascularization overall. OBJECTIVES:To evaluate the ability of PCSK9 inhibitors to reduce the risk of complex coronary atherosclerosis requiring revascularization. METHODS:FOURIER was a randomized trial of the PCSK9 inhibitor evolocumab vs. placebo in 27,564 patients ... Read more >>

J Am Coll Cardiol (Journal of the American College of Cardiology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



PCSK9 Inhibition-A Tale of 2 Potential Treatment Opportunities-Reply.

Brian A Bergmark, Marc S Sabatine,

JAMA Cardiol (JAMA cardiology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials.

Baris Gencer, Nicholas A Marston, KyungAh Im, Christopher P Cannon, Peter Sever, Anthony Keech, Eugene Braunwald, Robert P Giugliano, Marc S Sabatine,

BACKGROUND:The clinical benefit of LDL cholesterol lowering treatment in older patients remains debated. We aimed to summarise the evidence of LDL cholesterol lowering therapies in older patients. METHODS:In this systematic review and meta-analysis, we searched MEDLINE and Embase for articles published between March 1, 2015, and Aug 14, 2020, without ... Read more >>

Lancet (Lancet (London, England))
[2020, 396(10263):1637-1643]

Cited: 0 times

View full text PDF listing >>



Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition.

Daniel P Marcusa, Robert P Giugliano, Jeong-Gun Park, James A de Lemos, Christopher P Cannon, Marc S Sabatine,

Importance:Low-density lipoprotein cholesterol (LDL-C) is an important modifiable risk factor for atherosclerotic cardiovascular disease. It is unclear whether the percentage LDL-C lowering with pharmacotherapies differs on the basis of baseline LDL-C levels. Objective:To evaluate the association between baseline LDL-C levels and the percentage LDL-C reduction with a statin, ezetimibe, and ... Read more >>

JAMA Cardiol (JAMA cardiology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?

Su E Yeoh, Pooja Dewan, Pardeep S Jhund, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Scott D Solomon, Olof Bengtsson, Mikaela Sjöstrand, Anna Maria Langkilde, John Jv McMurray,

Background: The impact of heart failure (HF) duration on outcomes and treatment effect is largely unknown. We aim to compare baseline patient characteristics, outcomes and the efficacy and safety of dapagliflozin, in relation to time from diagnosis of HF in DAPA-HF. Methods: HF duration was categorized as ≥2 to ≤12 ... Read more >>

Circ Heart Fail (Circulation. Heart failure)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines.

Nicholas A Marston, Marc P Bonaca, Petr Jarolim, Erica L Goodrich, Deepak L Bhatt, Philippe G Steg, Marc Cohen, Robert F Storey, Per Johanson, Stephen D Wiviott, Eugene Braunwald, Marc S Sabatine, David A Morrow,

Importance:The 2018 American Heart Association/American College of Cardiology (AHA/ACC) cholesterol management guidelines identified 2 distinct groups of patients with atherosclerotic cardiovascular disease (ASCVD) prompting different treatment recommendations. Objective:To investigate whether the addition of high-sensitivity troponin (hsTn) testing to guideline-derived ASCVD risk can improve risk classification and downstream treatment recommendations. Design, ... Read more >>

JAMA Cardiol (JAMA cardiology)
[2020, 5(11):1255-1262]

Cited: 0 times

View full text PDF listing >>



Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy.

Batric Popovic, Emmanuel Sorbets, Jeremie Abtan, Marc Cohen, Charles V Pollack, Christoph Bode, Stephen D Wiviott, Marc S Sabatine, Shamir R Mehta, Witold Ruzyllo, Sunil V Rao, William J French, Prafulla Kerkar, Robert G Kiss, Jose Luis N Estrada, Yedid Elbez, Gregory Ducrocq, Philippe Gabriel Steg, ,

BACKGROUND:Previous studies published before the era of systematic early invasive strategy have reported a higher mortality in non-ST-segment elevation myocardial infarction patients with heart failure. The aim of our study was to compare the clinical characteristics, outcomes and causes of death of patients according to their heart failure status at ... Read more >>

Eur Heart J Acute Cardiovasc Care (European heart journal. Acute cardiovascular care)
[2020, :2048872619896205]

Cited: 0 times

View full text PDF listing >>



Response by Marston et al to Letter Regarding Article, "The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism".

Nicholas A Marston, Christian T Ruff, Marc S Sabatine,

Circulation (Circulation)
[2020, 142(17):e264]

Cited: 0 times

View full text PDF listing >>



Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Results of DAPA-HF.

Pardeep S Jhund, Scott D Solomon, Kieran F Docherty, Hiddo J L Heerspink, Inder S Anand, Michael Böhm, Vijay Chopra, Rudolf A de Boer, Akshay S Desai, Junbo Ge, Masafumi Kitakaze, Bela Merkely, Eileen O'Meara, Morten Schou, Sergey Tereshchenko, Subodh Verma, Pham Nguyen Vinh, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Olof Bengtsson, Anna Maria Langkilde, Mikaela Sjöstrand, John J V McMurray,

Background: Many patients with heart failure and reduced ejection fraction (HFrEF) have chronic kidney disease (CKD) which complicates pharmacological management and is associated with worse outcomes. We assessed the safety and efficacy of dapagliflozin in patients with HFrEF, according to baseline kidney function, in the Dapagliflozin and Prevention of Adverse-outcomes ... Read more >>

Circulation (Circulation)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Association of Hospital-Level Differences in Care With Outcomes Among Patients With Acute ST-Segment Elevation Myocardial Infarction in China.

Haiyan Xu, Yuejin Yang, Chuangshi Wang, Jingang Yang, Wei Li, Xuan Zhang, Yunqing Ye, Qiuting Dong, Rui Fu, Hui Sun, Xinxin Yan, Xiaojin Gao, Yang Wang, Xuan Jia, Yi Sun, Yuan Wu, Jun Zhang, Wei Zhao, Marc S Sabatine, Stephen D Wiviott, ,

Importance:The incidence of acute myocardial infarction has increased over the past decades in China, and management challenges include an unbalanced economy, disparate resources, and variable access to medical care across the nation. Objective:To examine the variations in care and outcomes of patients with ST-segment elevation myocardial infarction among 3 levels ... Read more >>

JAMA Netw Open (JAMA network open)
[2020, 3(10):e2021677]

Cited: 0 times

View full text PDF listing >>



Response by Zelniker et al to Letter Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial".

Thomas A Zelniker, Itamar Raz, Marc S Sabatine, Stephen D Wiviott,

Circulation (Circulation)
[2020, 142(10):e129-e130]

Cited: 0 times

View full text PDF listing >>



Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy.

Kieran F Docherty, Pardeep S Jhund, Olof Bengtsson, David L DeMets, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Anna Maria Langkilde, Felipe A Martinez, Marc S Sabatine, Mikaela Sjöstrand, Scott D Solomon, John J V McMurray, ,

OBJECTIVE:To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT). RESEARCH DESIGN AND METHODS:We examined the effect of study treatment by ... Read more >>

Diabetes Care (Diabetes care)
[2020, 43(11):2878-2881]

Cited: 0 times

View full text PDF listing >>



Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF.

Kieran F Docherty, Pardeep S Jhund, Inder Anand, Olof Bengtsson, Michael Böhm, Rudolf A de Boer, David L DeMets, Akshay S Desai, Jaroslaw Drozdz, Jonathan Howlett, Silvio E Inzucchi, Per Johanson, Tzvetana Katova, Lars Køber, Mikhail N Kosiborod, Anna Maria Langkilde, Daniel Lindholm, Felipe A Martinez, Béla Merkely, Jose C Nicolau, Eileen O'Meara, Piotr Ponikowski, Marc S Sabatine, Mikaela Sjöstrand, Scott D Solomon, Sergey Tereshchenko, Subodh Verma, John J V McMurray,

BACKGROUND:In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), dapagliflozin, added to guideline-recommended therapies, reduced the risk of mortality and heart failure (HF) hospitalization. We examined the frequency and significance of episodes of outpatient HF worsening, requiring the augmentation of oral therapy, and the effects of ... Read more >>

Circulation (Circulation)
[2020, 142(17):1623-1632]

Cited: 0 times

View full text PDF listing >>



Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).

Matteo Serenelli, Michael Böhm, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Scott D Solomon, David L DeMets, Olof Bengtsson, Mikaela Sjöstrand, Anna Maria Langkilde, Inder S Anand, Chern-En Chiang, Vijay K Chopra, Rudolf A de Boer, Mirta Diez, Andrej Dukát, Junbo Ge, Jonathan G Howlett, Tzvetana Katova, Masafumi Kitakaze, Charlotta E A Ljungman, Subodh Verma, Kieran F Docherty, Pardeep S Jhund, John J V McMurray,

AIMS:Concern about hypotension often leads to withholding of beneficial therapy in patients with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and safety of dapagliflozin, which lowers systolic blood pressure (SBP),according to baseline SBP in Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). METHODS ... Read more >>

Eur Heart J (European heart journal)
[2020, 41(36):3402-3418]

Cited: 0 times

View full text PDF listing >>



Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.

Avivit Cahn, Stephen D Wiviott, Ofri Mosenzon, Sabina A Murphy, Erica L Goodrich, Ilan Yanuv, Aliza Rozenberg, John P H Wilding, Lawrence A Leiter, Deepak L Bhatt, Darren K McGuire, Leon Litwak, Adriaan Kooy, Ingrid A M Gause-Nilsson, Martin Fredriksson, Anna Maria Langkilde, Marc S Sabatine, Itamar Raz,

AIM:To assess the associations between baseline glucose-lowering agents (GLAs) and cardiorenal outcomes with dapagliflozin versus placebo in the DECLARE-TIMI 58 study. MATERIALS AND METHODS:DECLARE-TIMI 58 assessed the cardiorenal outcomes of dapagliflozin versus placebo in patients with type 2 diabetes. This post hoc analysis elaborates the efficacy and safety outcomes by ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial.

Prakash Deedwania, Sabina A Murphy, Andre Scheen, Jolita Badariene, Armando Lira Pineda, Narimon Honarpour, Anthony C Keech, Peter S Sever, Terje R Pedersen, Marc S Sabatine, Robert P Giugliano,

Importance:The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER randomized clinical trial. Patients with metabolic syndrome (MetS) are at increased cardiovascular risk. Objective:To investigate outcomes with evolocumab in patients with and without MetS. Design, Setting, and Participants:The FOURIER trial randomized patients worldwide with stable atherosclerotic ... Read more >>

JAMA Cardiol (JAMA cardiology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.

Marc P Bonaca, Stephen D Wiviott, Thomas A Zelniker, Ofri Mosenzon, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, Erica L Goodrich, Remo Holanda De Mendonca Furtado, John P H Wilding, Avivit Cahn, Ingrid A M Gause-Nilsson, Per Johanson, Martin Fredriksson, Peter A Johansson, Anna Maria Langkilde, Itamar Raz, Marc S Sabatine,

BACKGROUND:Patients with peripheral artery disease (PAD) are at heightened risk of cardiovascular complications. The sodium-glucose cotransporter 2 inhibitor dapagliflozin reduces the risk for hospitalization for heart failure (HHF) and kidney events in patients with type 2 diabetes mellitus. An increased risk of amputation has been observed with canagliflozin in 1 ... Read more >>

Circulation (Circulation)
[2020, 142(8):734-747]

Cited: 0 times

View full text PDF listing >>



Biomarkers of platelet activation and cardiovascular risk in the DAPT trial.

David D Berg, Robert W Yeh, Laura Mauri, David A Morrow, Dean J Kereiakes, Donald E Cutlip, Qi Gao, Petr Jarolim, Alan D Michelson, Andrew L Frelinger, Abby L Cange, Marc S Sabatine, Michelle L O'Donoghue,

Prolonged use of dual antiplatelet therapy (DAPT) post-percutaneous coronary intervention (PCI) has been shown to reduce the risk of major adverse cardiovascular events (MACE), but with increased bleeding. It remains unknown whether biomarkers of platelet activation may be useful for identifying patients at increased risk of MACE. The DAPT study was ... Read more >>

J Thromb Thrombolysis (Journal of thrombosis and thrombolysis)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.

Alice M Jackson, Pooja Dewan, Inder S Anand, Jan Bělohlávek, Olof Bengtsson, Rudolf A de Boer, Michael Böhm, David W Boulton, Vijay K Chopra, David L DeMets, Kieran F Docherty, Andrej Dukát, Peter J Greasley, Jonathan G Howlett, Silvio E Inzucchi, Tzvetana Katova, Lars Køber, Mikhail N Kosiborod, Anna Maria Langkilde, Daniel Lindholm, Charlotta E A Ljungman, Felipe A Martinez, Eileen O'Meara, Marc S Sabatine, Mikaela Sjöstrand, Scott D Solomon, Sergey Tereshchenko, Subodh Verma, Pardeep S Jhund, John J V McMurray,

BACKGROUND:In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of worsening heart failure and death in patients with heart failure and reduced ejection fraction. We examined the efficacy and tolerability of dapagliflozin in relation to background diuretic treatment ... Read more >>

Circulation (Circulation)
[2020, 142(11):1040-1054]

Cited: 0 times

View full text PDF listing >>



Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial.

Stephen D Wiviott, Robert P Giugliano, David A Morrow, Gaetano M De Ferrari, Basil S Lewis, Kurt Huber, Julia F Kuder, Sabina A Murphy, Danielle M Forni, Christopher E Kurtz, Narimon Honarpour, Anthony C Keech, Peter S Sever, Terje R Pedersen, Marc S Sabatine,

Importance:The PCSK9 inhibitor evolocumab reduced major vascular events in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial, yet the types and sizes of myocardial outcomes in FOURIER have not been previously explored. Objective:To assess the types and sizes of myocardial infarction (MI) and ... Read more >>

JAMA Cardiol (JAMA cardiology)
[2020, 5(7):787-793]

Cited: 1 time

View full text PDF listing >>



Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial.

Scott D Solomon, Pardeep S Jhund, Brian L Claggett, Pooja Dewan, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Silvio E Inzucchi, Akshay S Desai, Olof Bengtsson, Daniel Lindholm, Mikaela Sjostrand, Anna Maria Langkilde, John J V McMurray,

OBJECTIVES:This study assessed the efficacy and safety of dapagliflozin in patients who were or were not taking sacubitril/valsartan at baseline in the DAPA-HF (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure) trial. BACKGROUND:Both the angiotensin ... Read more >>

JACC Heart Fail (JACC. Heart failure)
[2020, 8(10):811-818]

Cited: 0 times

View full text PDF listing >>



Effects of dapagliflozin in DAPA-HF according to background heart failure therapy.

Kieran F Docherty, Pardeep S Jhund, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, David L DeMets, Marc S Sabatine, Olof Bengtsson, Mikaela Sjöstrand, Anna Maria Langkilde, Akshay S Desai, Mirta Diez, Jonathan G Howlett, Tzvetana Katova, Charlotta E A Ljungman, Eileen O'Meara, Mark C Petrie, Morten Schou, Subodh Verma, Pham Nguyen Vinh, Scott D Solomon, John J V McMurray,

AIMS:In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined whether this benefit was consistent in relation to background HF therapy. METHODS AND RESULTS:In this post hoc analysis, we examined the effect ... Read more >>

Eur Heart J (European heart journal)
[2020, 41(25):2379-2392]

Cited: 3 times

View full text PDF listing >>



The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.

Michelle L O'Donoghue, Sabina A Murphy, Marc S Sabatine,

BACKGROUND:Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor has been shown to reduce the risk of major adverse cardiovascular events (MACE) compared with aspirin alone after percutaneous coronary intervention (PCI) or acute coronary syndrome but with increased risk of bleeding. The safety of discontinuing aspirin in favor of P2Y12 ... Read more >>

Circulation (Circulation)
[2020, 142(6):538-545]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.3761 s